Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kenta Biotech, a developer of human monoclonal antibodies, has raised $10 million in a series B private financing from the existing investors.
Subscribe to our email newsletter
The proceeds will be used for the ongoing clinical development of KBPA 101 in nosocomial pneumonia and to advance KBSA 201, a fully human IgG monoclonal antibody against methicilin-resistant Staphylococcus aureus, from preclinical into clinical development.
Kenta’s lead-product KBPA 101, an IgM antibody targeting Pseudomonas aeruginosa, is currently being studied in a Phase IIa study for treatment of nosocomial pneumonia in Switzerland and EU-countries. Results are expected later in 2009.
Violetta Georgescu-Kyburz, CEO of Kenta Biotech, said: “We are delighted to secure this financing, which marks the next phase for our company and enables us to move our highly innovative antibody programmes towards the clinic. In addition, it demonstrates the strength of the company and the commitment of our shareholders.”